BusinessRadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumorsBy Nasdaq OMXJan 10, 2018, 10:00 AM UTC
BusinessRadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumorsBy Nasdaq OMXJun 22, 2017, 8:00 PM UTC
BusinessRadioMedix and AREVA Med – SBIR NCI Contract Grant awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212By Nasdaq OMXNov 1, 2016, 5:00 AM UTC
BusinessAREVA Med Inaugurates Second Lead-212 Production FacilityBy Nasdaq OMXApr 13, 2016, 7:23 PM UTC
BusinessAREVA Med Partners With Art Institute of Dallas (U.S.) and École Supérieure de Design Troyes (France)By Nasdaq OMXFeb 29, 2016, 6:30 PM UTC
